PDL BioPharma Names Dr. Jill Jene Vice President, Business Development
PDL BioPharma Names Dr. Jill Jene Vice President, Business Development |
[21-May-2018] |
INCLINE VILLAGE, Nev., May 21, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) announces the appointment of Jill M. Jene, Ph.D. as Vice President, Business Development. Dr. Jene will lead the efforts to add healthcare assets to PDL's portfolio of products and companies. She will report to PDL President, Dominique Monnet. "Jill brings to PDL more than 20 years of biopharmaceutical business development experience and an exceptional track-record of success spanning more than $3 billion in licensing and M&A transactions," said Mr. Monnet. "We look forward to her expertise in identifying opportunities and creating novel deal structures that support our goal of increasing shareholder value by expanding our portfolio of biopharmaceutical companies and products. Jill is exceptionally qualified to fill this critical position, and we are delighted to welcome her to PDL." "PDL has the managerial expertise and the balance sheet to capitalize on a range of acquisitions and product opportunities that fit its strategic objectives," said Dr. Jene. "I'm excited to be working with the PDL team to generate a pipeline of qualified targets and to consummate transactions that expand the Company's portfolio." Prior to PDL, Dr. Jene was Senior Vice President, Business Development at twoXAR, where she revamped the business development process, generated a pipeline of opportunities and negotiated deal terms for collaborations, spinouts and licenses. Previously, she was with Depomed for 11 years rising to Vice President, Business Development. At Depomed she was instrumental in closing more than 20 transactions, including the acquisition of four commercial franchises. Earlier in her career, Dr. Jene held positions of increasing responsibilities in business development at Cell Genesys, 3M Company and Baxter International. Dr. Jene holds a Ph.D. and MS in chemistry from Northwestern University, an MBA from DePaul University and a BS in chemistry from Bradley University. About PDL BioPharma PDL operates in three segments designated as Income Generating Assets, Pharmaceutical and Medical Devices. NOTE: PDL, PDL BioPharma, the PDL logo and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary, to PDL BioPharma, Inc., which reserves all rights therein. Forward-Looking Statements
View original content with multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-names-dr-jill-jene-vice-president-business-development-300651638.html SOURCE PDL BioPharma, Inc. | ||
Company Codes: NASDAQ-NMS:PDLI |
© 2018 PR Newswire. All Rights Reserved.